UCB (OTCMKTS:UCBJY) Stock Rating Raised to Strong-Buy at Zacks Research

UCB (OTCMKTS:UCBJY) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday, Zacks reports.

Separately, Jefferies Financial Group raised UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy”.

UCB Trading Up 0.8%

Shares of OTCMKTS:UCBJY opened at $150.83 on Tuesday. The stock has a fifty day simple moving average of $123.20 and a two-hundred day simple moving average of $140.08. UCB has a 12-month low of $110.55 and a 12-month high of $168.76.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases in neurology and immunology. The company serves patients and healthcare professionals internationally, with operations and commercial activities spanning Europe, North America and other global markets.

UCB’s neurology portfolio includes medicines such as Vimpat (lacosamide) and Briviact (brivaracetam) for epilepsy, as well as Fintepla (fenfluramine) for certain seizure disorders.